Table 1.

Patient, tumor, and treatment characteristics by route of administration

Route of vaccine administration
IL, n = 19IN, n = 19ILN, n = 16
Mean ± SERangeMean ± SERangeMean ± SERange
Age, years54.8 ± 1.536–6852.0 ± 2.137–6356.6 ± 2.935–83
BMI25.9 ± 1.519–3927.2 ± 1.320–3828.7 ± 1.822–51
n%n%n%
Race
 Caucasian1578.91473.71487.5
 African-American210.5315.8212.5
 Hispanic00.0210.500.0
 Asian210.500.000.0
Menopausal status
 Premenopausal315.8526.3318.8
 Postmenopausal1684.21473.71381.3
Charlson comorbidity score
 ≤21789.51789.51487.5
 ≥3210.5210.5212.5
Current medications
 None15.3210.5212.5
 <51263.21157.91168.8
 >5631.6631.6318.8
Gradea
 Low15.300.000.0
 Intermediate421.1738.9318.8
 High1473.71161.11381.3
Stage
 DCIS1368.41684.21381.3
 IBCb631.6315.8318.8
ER status
 Negative842.11157.9637.5
 Positive1157.9842.11062.5
PR status
 Negative1157.91368.4743.8
 Positive842.1631.6956.3
HER2/neu status
 2+631.6631.6743.8
 3+1368.41368.4956.3
Surgery & radiation
 Lumpectomy, no radiation947.41052.6743.8
 Lumpectomy, radiation421.1210.5637.5
 Mastectomy631.6736.8318.8
  • Abbreviations: BMI, body mass index; PR, progesterone index.

  • aTumor grade missing for 1 patient who received an intranodal injection.

  • bPrior to vaccination, 3 patients were diagnosed with IBC by biopsy; following vaccination, an additional 9 patients who were initially diagnosed with DCIS were upstaged to IBC in the final surgical specimen (IL, 2 patients diagnosed by biopsy, 4 patients upstaged; IN, 1 patient diagnosed by biopsy, 2 patients upstaged; ILN, 0 patients diagnosed by biopsy, 3 patients upstaged).